Issue link: https://www.e-digitaleditions.com/i/1087673
Tablets & Capsules March 2019 9 Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemo- therapy. Sprycel is the only sec- ond-generation tyrosine kinase inhibitor approved as a treatment for this patient population. It is manufactured by Bristol-Myers Squibb, New York, NY. generic names, and avoid errors in reports, correspondence, articles, and package inserts. The dictionary can be accessed at www.usp.org/prod ucts/usp-dictionary. FDA expands Imbruvica label to include CLL/SLL SILVER SPRINGS, MD—The FDA approved a label expansion for Imbruvica (ibrutinib) in combination with obinutuzumab to treat adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It is manufactured by Abbvie, North Chicago, IL. Civica Rx welcomes 12 new founding members SALT LAKE CITY, UT—Civica Rx, a not-for-profit generic pharma- ceutical manufacturer, has accepted 12 health systems representing 250 US hospitals as founding members. They include Advocate Aurora Health, Allegheny Health Network, B a p t i s t H e a l t h S o u t h F l o r i d a , F r a n c i s c a n A l l i a n c e , M e m o r i a l Hermann Health System, NYU Langone Health, Ochsner Health System, Sanford Health, Spectrum Health, St. Luke's University Health Network, Steward Health Care, and UnityPoint Health. In other news, Reuters reports that Civica Rx expects to provide 20 generic products in 2019 to alleviate shortages for medicines used during surgeries and for treating life-threat- ening conditions, such as septic shock. The company had initially expected to offer 14 products this year but has forged relationships with several companies with licenses to manufacture additional medicines. The company's goal is to offer as many as 100 generic drug products within three to five years. FDA expands Sprycel indication to include pediatric treatment for Ph+ ALL S I L V E R S P R I N G , M D — T h e FDA approved a label expansion for Sprycel (dasatinib) as a treatment for pediatric patients age one and o l d e r w i t h n e w l y d i a g n o s e d SM First-rate, free advice for clean labels. Contact Clean Label Alliance Today! CleanLabelAlliance.com Subscribe today www.tabletscapsules.com